Tranexamic acid (TXA) is a potent antifibrinolytic with documented efficacy in reducing blood
loss and allogeneic red blood cell transfusion in several clinical settings. With a growing …

Artificial intelligence is finding several applications in healthcare settings. This study aimed
to report evidence on the effectiveness of artificial intelligence application in obstetrics …

Objective This guideline aims to provide evidence for prevention, recognition, and treatment
of postpartum hemorrhage including severe hemorrhage leading to hemorrhagic shock …

Introduction Over the last decade, tranexamic acid (TXA) has been incorporated into
treatment algorithms for a multitude of emergent conditions and the evidence surrounding its …

Partial quantitative deficiency of plasma von Willebrand factor (VWF) is responsible for the
majority of cases of von Willebrand disease (VWD), the most common inherited human …

Resumen Introducción: En Colombia la hemorragia postparto es la segunda causa de
mortalidad en mujeres gestantes de 24 a 34 años con 6, 9 casos por cada 1000 nacidos …

Antifibrinolytic agents such as tranexamic acid (TXA) inhibit the fibrinolytic pathway and
protect blood clots from being degraded, thereby promoting hemostasis. They have been …

Background To determine the prevalence, related factors and maternal outcomes of primary
PPH in governmental hospitals in Kabul Afghanistan. Methods An observational study was …

Background In this meta-analysis, we aimed to update the clinical evidence regarding the
efficacy and safety of TXA in the prevention of PPH. Methods A literature search of PubMed …

Background: Tranexamic acid (TA) has been demonstrated to reduce blood loss and the
incidences of postpartum hemorrhage (PPH) during caesarean sections. We compared the …